Fig.1 In vivo efficacy assessment of RVT3101, Tulisokibart and Duvakitug in the TBNS-induced acute colitis model of HO hTL1A(3) mice.

(A) Body weight change and (B) DAI score in the TBNS-induced acute colitis model of hTL1A(3) mice. In this study, all hTL1A mice were randomly divided into experimental and control cohorts groups on Day -1. The treatment groups received intraperitoneal injections of anti-human TL1A antibody RVT-3101 and Tulisokibart (25mpk), the TL1A inhibitor Duvakitug (25mpk) every three days for a total of two doses. The acute colitis model was established in hTL1A mice by a single intrarectal injection of 1.5% TNBS on Day 0. Body weight and DAI score were recorded daily. (n=6 females per group, 15-16 weeks old, Mean ± SEM, Unpaired t-test, *P<0.05, **P<0.01, ***P<0.0001)

Fig.2 In vivo efficacy assessment of RVT3101, Tulisokibart and Duvakitug in the TBNS-induced acute colitis model of HO hTL1A(3) mice.

(A) Colon index. (B) Colon photo. On Day 5, all mice were sacrificed, and the isolated colons were subjected to weight and photograph. The results demonstrated that, compared with the control group, treatment groups exhibited a significant amelioration of TBNS-induced acute colitis in hTL1A mice. (n=6 females per group, 15-16 weeks old, Mean ± SEM, Unpaired t-test, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001)

Fig.3 In vivo efficacy assessment of RVT3101, Tulisokibart and Duvakitug in the TBNS-induced acute colitis model of HO hTL1A(3) mice.

Histopathological evaluation of colon tissues in the TBNS-induced acute colitis of hTL1A(3) mice. On Day 5, all mice were sacrificed, and the isolated colons were subjected to embed in paraffin with HE staining. Treatment with Duvakitug and RVT-3101 significantly improved TBNS-induced acute colitis in hTL1A mice. (n=6 females per group, 15-16 weeks old, Mean ± SEM, Unpaired t-test, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001)